Literature DB >> 17396729

Early and late arrhythmogenic effects of doxorubicin.

Saadettin Kilickap1, Ibrahim Barista, Ebru Akgul, Kudret Aytemir, Sercan Aksoy, Gulten Tekuzman.   

Abstract

BACKGROUND: To determine the incidence of early and late arrhythmogenic effects of doxorubicin-containing chemotherapy regimens. PATIENTS AND METHODS: A prospective study including 29 patients who were treated with doxorubicin-containing regimens. Cardiac evaluation was based on 24-hour electrocardiographic monitorization (Holter), which was performed during the first cycle of doxorubicin-containing regimens, as well as after the last cycle of chemotherapy.
RESULTS: The mean age of the patients was 45.8 +/- 15.1 (range 18-69). Holter records obtained during the first cycle of treatment revealed varying arrhythmias in 19 patients (65.5%) and in 18 (62.1%) patients after completion of therapy. One patient presented with syncope and both Mobitz Type 2 atrioventricular block and complete atrioventricular block were demonstrated. The patient subsequently underwent permanent pacemaker implantation.
CONCLUSIONS: Doxorubicin may result in arrhythmias both in early and late periods of treatment. These arrhythmias are rarely life threatening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396729     DOI: 10.1097/01.smj.0000257382.89910.fe

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  22 in total

Review 1.  Electrophysiologic Complications in Cancer Patients.

Authors:  Dae Hyun Lee; Sanjay Chandrashekhar; Michael G Fradley
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 2.  Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.

Authors:  Federico Viganego; Robin Singh; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

Review 3.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 4.  Atrial Fibrillation and Cancer Patients: Mechanisms and Management.

Authors:  David L Madnick; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2022-08-17       Impact factor: 3.955

Review 5.  Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.

Authors:  Wei Huang; Rong Xu; Bin Zhou; Chao Lin; Yingkun Guo; Huayan Xu; Xia Guo
Journal:  Front Cardiovasc Med       Date:  2022-06-10

Review 6.  Drug-induced atrial fibrillation.

Authors:  Yaman Kaakeh; Brian R Overholser; John C Lopshire; James E Tisdale
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

7.  Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.

Authors:  Saadettin Kilickap; Bunyamin Yavuz; Sercan Aksoy; Levent Sahiner; Murat Dincer; Hakan Harputluoglu; Mustafa Erman; Kudret Aytemir; Lale Tokgozoglu; Ibrahim Barista
Journal:  Med Oncol       Date:  2008-04-15       Impact factor: 3.064

Review 8.  The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.

Authors:  Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-12       Impact factor: 4.733

Review 9.  Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.

Authors:  Michael G Fradley; Theresa M Beckie; Sherry Ann Brown; Richard K Cheng; Susan F Dent; Anju Nohria; Kristen K Patton; Jagmeet P Singh; Brian Olshansky
Journal:  Circulation       Date:  2021-06-17       Impact factor: 29.690

Review 10.  Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.

Authors:  Elvira C van Dalen; Helena J H van der Pal; Leontien C M Kremer
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.